Progress in the Study of C5a and Coronary Heart Disease

DOI: https://doi.org/10.62517/jmhs.202505216

Author(s)

Yang Yang, Zhang Zhen*

Affiliation(s)

Hunan Normal University Affiliated Xiangdong Hospital, Zhuzhou , Hunan, China *Corresponding Author

Abstract

This article reviews recent research progress on C5a and coronary heart disease and discusses its potential mechanisms and clinical applications in disease onset and progression. First, C5a is a highly active complement component that plays an important role in immune and inflammatory responses. In recent years, more and more studies have focused on its role in coronary heart disease. Its mechanism consists of three main aspects: inflammatory response, thrombosis and atherosclerosis.C5a exacerbates the formation and rupture of atherosclerotic plaques by activating the inflammatory pathway, promoting cytokine secretion and inflammatory cell infiltration. It also enhances platelet aggregation and coagulation factor release, thereby promoting thrombosis. Clinical studies have further validated the importance of C5a in patients with coronary artery disease and found that it may not only serve as a biomarker for cardiovascular risk prediction, but also has potential clinical diagnostic and prognostic value. In terms of treatment, clinical intervention strategies for C5a need to be further validated for safety and efficacy. In summary, the role of C5a in the development of coronary heart disease and its potential as a therapeutic target are receiving increasing attention. Future research will focus on further revealing its specific mechanism of action and optimizing the clinical application of the blocker. This not only has the potential to improve the therapeutic efficacy of coronary artery disease, but will also promote the development of complement system-related research. With the deeper understanding of C5a function and the promotion of blockers, it is expected that this target will play an increasingly important role in coronary heart disease treatment.

Keywords

C5a; Coronary Heart Disease; Inflammatory Response; Atherosclerosis; Thrombosis

References

[1] Martin S S, Aday A W, Almarzooq Z I, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association [J]. Circulation, 2024, 149(8): e347-e913. [2] Ma M, Liu Y, Wang L, et al. Relationship Between Monocyte-to-Lymphocyte Ratio as Well as Other Leukocyte-Derived Ratios and Carotid Plaques in Patients with Coronary Heart Disease: A RCSCD-TCM Study [J]. J Inflamm Res, 2022, 15: 5141-56. [3] Lu Y, Liu H, Dong B, et al. Correlation between platelet-derived growth factor-B gene polymorphism and coronary heart disease [J]. J Clin Lab Anal, 2022, 36(10): e24683. [4] West E E, Kemper C. Complosome - the intracellular complement system [J]. Nat Rev Nephrol, 2023, 19(7): 426-39. [5] Bergmann M, Jeanneau C, Giraud T, et al. Complement activation links inflammation to dental tissue regeneration [J]. Clin Oral Investig, 2020, 24(12): 4185-96. [6] Bavia L, Lidani K C F, Andrade F A, et al. Complement activation in acute myocardial infarction: An early marker of inflammation and tissue injury? [J]. Immunol Lett, 2018, 200: 18-25. [7] Ghosh M, Rana S. The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics [J]. Int Immunopharmacol, 2023, 118: 110081. [8] Busche M N, Stahl G L. Role of the complement components C5 and C3a in a mouse model of myocardial ischemia and reperfusion injury [J]. Ger Med Sci, 2010, 8. [9] Vahldieck C, Löning S, Hamacher C, et al. Dysregulated complement activation during acute myocardial infarction leads to endothelial glycocalyx degradation and endothelial dysfunction via the C5a:C5a-Receptor1 axis [J]. Front Immunol, 2024, 15: 1426526. [10] Hajishengallis G, Reis E S, Mastellos D C, et al. Novel mechanisms and functions of complement [J]. Nat Immunol, 2017, 18(12): 1288-98. [11] Klos A, Wende E, Wareham K J, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors [J]. Pharmacol Rev, 2013, 65(1): 500-43. [12] Möller T, Nolte C, Burger R, et al. Mechanisms of C5a and C3a complement fragment-induced [Ca2+]i signaling in mouse microglia [J]. J Neurosci, 1997, 17(2): 615-24. [13] Sayah S, Jauneau A C, Patte C, et al. Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes [J]. Brain Res Mol Brain Res, 2003, 112(1-2): 53-60. [14] Monk P N, Scola A M, Madala P, et al. Function, structure and therapeutic potential of complement C5a receptors [J]. Br J Pharmacol, 2007, 152(4): 429-48. [15] Pandey S, Maharana J, Li X X, et al. Emerging Insights into the Structure and Function of Complement C5a Receptors [J]. Trends Biochem Sci, 2020, 45(8): 693-705. [16] Ehrnthaller C, Braumüller S, Kellermann S, et al. Complement Factor C5a Inhibits Apoptosis of Neutrophils-A Mechanism in Polytrauma? [J]. J Clin Med, 2021, 10(14). [17] Guo W Y, Wang G Q, Kong L Q, et al. Complement system is overactivated in patients with IgA nephropathy after COVID-19 [J]. Clin Immunol, 2024, 263: 110232. [18] Zhu P, Ji W, Li D, et al. The activation of complement C5a-C5aR1 axis in astrocytes facilitates the neuropathogenesis due to EV-A71 infection by upregulating CXCL1 [J]. J Virol, 2025, 99(1): e0151424. [19] Wezel A, de Vries M R, Lagraauw H M, et al. Complement factor C5a induces atherosclerotic plaque disruptions [J]. J Cell Mol Med, 2014, 18(10): 2020-30. [20] An G, Ren G, An F, et al. Role of C5a-C5aR axis in the development of atherosclerosis [J]. Sci China Life Sci, 2014, 57(8): 790-4. [21] An G, Li B, Liu X, et al. Overexpression of complement component C5a accelerates the development of atherosclerosis in ApoE-knockout mice [J]. Oncotarget, 2016, 7(35): 56060-70. [22] Laumonnier Y, Karsten C M, Köhl J. Novel insights into the expression pattern of anaphylatoxin receptors in mice and men [J]. Mol Immunol, 2017, 89: 44-58. [23] Bosmann M, Ward P A. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis [J]. Adv Exp Med Biol, 2012, 946: 147-59. [24] Song Fei, Yu Mengyue, Liu Jianru, et al. The effect of complement system homeostasis on the severity of coronary atherosclerosis [J]. Chinese Journal of Laboratory Medicine, 2016, 39 (9): 685-9 [25] Guo R F, Ward P A. Role of C5a in inflammatory responses [J]. Annu Rev Immunol, 2005, 23: 821-52. [26] Otsuka F, Yasuda S, Noguchi T, et al. Pathology of coronary atherosclerosis and thrombosis [J]. Cardiovasc Diagn Ther, 2016, 6(4): 396-408. [27] Chen Y, Li X, Lin X, et al. Complement C5a induces the generation of neutrophil extracellular traps by inhibiting mitochondrial STAT3 to promote the development of arterial thrombosis [J]. Thromb J, 2022, 20(1): 24. [28] Kurosawa S, Stearns-Kurosawa D J. Complement, thrombotic microangiopathy and disseminated intravascular coagulation [J]. J Intensive Care, 2014, 2(1): 65. [29] Lim M S, McRae S. COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications [J]. Crit Rev Oncol Hematol, 2021, 168: 103529. [30] Niyonzima N, Bakke S S, Gregersen I, et al. Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis [J]. EBioMedicine, 2020, 60: 102985. [31] Liu A, Chen Z, Li X, et al. C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification via PERK-eIF2α-ATF4-CREB3L1 pathway [J]. Cardiovasc Res, 2023, 119(15): 2563-78. [32] Hernández-Díaz M, Rodríguez-González D, Heras-Recuero E, et al. The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis [J]. Arthritis Res Ther, 2024, 26(1): 127. [33] Shagdarsuren E, Bidzhekov K, Mause S F, et al. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice [J]. Circulation, 2010, 122(10): 1026-36.